메뉴 건너뛰기




Volumn 30, Issue 6, 2010, Pages 887-892

High-molecular-weight aggregates in repackaged bevacizumab

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN HEAVY CHAIN; PLACEBO;

EID: 77953358874     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181d50cea     Document Type: Article
Times cited : (116)

References (22)
  • 1
    • 70349469696 scopus 로고    scopus 로고
    • Antiangiogenic approaches to age-related macular degeneration today
    • Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009;116:S15-S23.
    • (2009) Ophthalmology , vol.116
    • Bressler, N.M.1
  • 2
    • 65549162660 scopus 로고    scopus 로고
    • Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration
    • Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158-165.
    • (2009) Curr Opin Ophthalmol , vol.20 , pp. 158-165
    • Ciulla, T.A.1    Rosenfeld, P.J.2
  • 3
    • 33750296920 scopus 로고    scopus 로고
    • The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide
    • Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
    • (2006) Br J Ophthalmol , vol.90 , pp. 1344-1349
    • Fung, A.E.1    Rosenfeld, P.J.2    Reichel, E.3
  • 4
    • 67649884473 scopus 로고    scopus 로고
    • Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration
    • Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 2009;223:370-375.
    • (2009) Ophthalmologica , vol.223 , pp. 370-375
    • Landa, G.1    Amde, W.2    Doshi, V.3
  • 7
    • 77953360250 scopus 로고    scopus 로고
    • Avastin and Risk of Glaucoma
    • September 30-October 4, . New York, NY. Abstract
    • Carver J, Bouska C, Corey R. Avastin and Risk of Glaucoma. Retina Congress 2009 New York, September 30-October 4, 2009. New York, NY. Abstract.
    • (2009) Retina Congress 2009 New York
    • Carver, J.1    Bouska, C.2    Corey, R.3
  • 8
    • 37749036215 scopus 로고    scopus 로고
    • Intravitreal bevacizumab (Avastin) causing acute glaucoma: An unreported complication
    • Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye 2007;21:1541.
    • (2007) Eye , vol.21 , pp. 1541
    • Jalil, A.1    Fenerty, C.2    Charles, S.3
  • 9
    • 0026516665 scopus 로고
    • Unexpected interaction of some anti-TNP hybridoma antibodies with Superose HPLC gel filtration resins
    • Michaelsen TE, Lofsgaard MF, Aase A, Heyman B. Unexpected interaction of some anti-TNP hybridoma antibodies with Superose HPLC gel filtration resins. J Immunol Methods 1992;146:9-16.
    • (1992) J Immunol Methods , vol.146 , pp. 9-16
    • Michaelsen, T.E.1    Lofsgaard, M.F.2    Aase, A.3    Heyman, B.4
  • 10
    • 33645641520 scopus 로고    scopus 로고
    • Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study
    • Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633.el-e4.
    • (2006) Ophthalmology , vol.113
    • Heier, J.S.1    Antoszyk, A.N.2    Pavan, P.R.3
  • 11
    • 33745771388 scopus 로고    scopus 로고
    • Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing
    • Bakri SJ, Snyder MR, Pulido JS, McCannel CA, Weiss WT, Singh RJ. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006;26: 519-522.
    • (2006) Retina , vol.26 , pp. 519-522
    • Bakri, S.J.1    Snyder, M.R.2    Pulido, J.S.3    McCannel, C.A.4    Weiss, W.T.5    Singh, R.J.6
  • 12
    • 0141567459 scopus 로고    scopus 로고
    • Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation
    • Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003;20:1325-1336.
    • (2003) Pharm Res , vol.20 , pp. 1325-1336
    • Chi, E.Y.1    Krishnan, S.2    Randolph, T.W.3    Carpenter, J.F.4
  • 13
    • 68949085124 scopus 로고    scopus 로고
    • Protein aggregation: Pathways, induction factors and analysis
    • Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 2009;98:2909-2934.
    • (2009) J Pharm Sci , vol.98 , pp. 2909-2934
    • Mahler, H.C.1    Friess, W.2    Grauschopf, U.3    Kiese, S.4
  • 14
    • 52449090177 scopus 로고    scopus 로고
    • Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways
    • Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci 2008;97:2924-2935.
    • (2008) J Pharm Sci , vol.97 , pp. 2924-2935
    • Kerwin, B.A.1
  • 17
    • 68949119488 scopus 로고    scopus 로고
    • Monoclonal antibody inter actions with micro- and nanoparticles: Adsorption, aggregation and accelerated stress studies
    • Bee JS, Chui D, Sawicki S, et al. Monoclonal antibody inter actions with micro- and nanoparticles: adsorption, aggregation and accelerated stress studies. J Pharm Sci 2009;98:3218-3238.
    • (2009) J Pharm Sci , vol.98 , pp. 3218-3238
    • Bee, J.S.1    Chui, D.2    Sawicki, S.3
  • 19
    • 70349263362 scopus 로고    scopus 로고
    • Evaluation of the immunostimulatory potential of stopper extractables and leachables by using dendritic cells as readout
    • Mueller R, Karle A, Vogt A, et al. Evaluation of the immunostimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J Pharm Sci 2009;98:3548-3561.
    • (2009) J Pharm Sci , vol.98 , pp. 3548-3561
    • Mueller, R.1    Karle, A.2    Vogt, A.3
  • 20
    • 64849085452 scopus 로고    scopus 로고
    • Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)
    • GeorgopoulosM, Polak K, Prager F, Prunte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-462.
    • (2009) Br J Ophthalmol , vol.93 , pp. 457-462
    • Georgopoulos, M.1    Polak, K.2    Prager, F.3    Prunte, C.4    Schmidt-Erfurth, U.5
  • 21
    • 0015467326 scopus 로고
    • Chronic open-angle glaucoma secondary to rhegmatogenous retinal detachment
    • Schwartz A. Chronic open-angle glaucoma secondary to rhegmatogenous retinal detachment. Trans Am Ophthalmol Soc 1972;70:178-189.
    • (1972) Trans Am Ophthalmol Soc , vol.70 , pp. 178-189
    • Schwartz, A.1
  • 22
    • 0035888982 scopus 로고    scopus 로고
    • Experimental glaucoma in the primate induced by latex microspheres
    • Weber AJ, Zelenak D. Experimental glaucoma in the primate induced by latex microspheres. J Neurosci Methods 2001;111: 39-48.
    • (2001) J Neurosci Methods , vol.111 , pp. 39-48
    • Weber, A.J.1    Zelenak, D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.